HDL research must continue (via the heart.org)
> After a series of negative trial results, the concept of raising high-density lipoprotein (HDL) as a therapeutic approach to reducing cardiovascular risk looks to be in a sorry state. But lipid experts at the recent European Atherosclerosis Society (EAS) 2012 Congress were adamant that the HDL hypothesis was not yet dead and that it is imperative that research in this direction continue.
What do you think? Do you hold out any hope for this method of lowering CV risk? Should we wait for the results of the phase 3 anacetrapib study? What about the HPS2-thrive study with Niacin? Do we have to wait until 2013 or should we withdraw Niacin today?